RadNet's (RDNT) Buy Rating Reaffirmed at Truist Financial
Truist Financial reissued their buy rating on shares of RadNet (NASDAQ:RDNT – Free Report) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $63.00 price objective on the medical research company’s stock, up from their prior price objective of $55.00. A number of other analysts have also recently commented on […]